U.S. FOOD & DRUG ADMINISTRATION

Our STN: BL 103980/6252

**SUPPLEMENT APPROVAL**
September 30, 2025

Baxter Healthcare Corporation
Attention: Stephanie Hughes
25212 W. Illinois Route 120
Round Lake, IL 60073

Dear Stephanie Hughes:

We have approved your request received March 31, 2025, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Fibrin Sealant [TISSEEL]. The approved supplement expands the indication of TISSEEL for use in adult and pediatric patients as an adjunct to hemostasis when control of bleeding by conventional surgical techniques is ineffective or impractical and as an adjunct to standard surgical techniques to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. Additionally, the US prescribing information was updated to optimize instructions for preparation and reconstitution of TISSEEL, update the mean viral reduction factors, and remove references to discontinued AST syringe.

## LABELING

We hereby approve the draft content of labeling Package Insert submitted BL 103980/6252.5004, dated September 30, 2025.

## CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package submitted on September 30, 2025. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 103980 at the time of use and include implementation information on Form FDA 356h.

**ADVERTISING AND PROMOTIONAL LABELING**

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Asha Das, MD
Acting Director
Division of Clinical Evaluation General Medicine
Office of Clinical Evaluation
Office of Therapeutic Products
Center for Biologics Evaluation and Research